Explore peer-reviewed studies on antimicrobial resistance, sterilization protocols, and outbreak management
Comprehensive analysis of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD) for ER+/HER2- advanced breast cancer treatment.